Hemab Therapeutics (NASDAQ:COAG) Shares Up 6% – Here’s What Happened
by Scott Moore · The Cerbat GemHemab Therapeutics Holdings, Inc. (NASDAQ:COAG – Get Free Report)’s share price shot up 6% on Thursday. The company traded as high as $30.65 and last traded at $30.43. 238,850 shares traded hands during mid-day trading, a decline of 36% from the average session volume of 376,088 shares. The stock had previously closed at $28.70.
Analysts Set New Price Targets
A number of research analysts recently issued reports on COAG shares. Jefferies Financial Group raised their target price on shares of Hemab Therapeutics from $39.00 to $47.00 and gave the company a “buy” rating in a research note on Monday, July 13th. HC Wainwright upped their price target on shares of Hemab Therapeutics from $52.00 to $60.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Wedbush raised their price target on Hemab Therapeutics from $55.00 to $64.00 and gave the company an “outperform” rating in a research report on Wednesday, August 12th. Finally, Weiss Ratings lowered Hemab Therapeutics from a “sell (d+)” rating to a “sell (d)” rating in a research note on Friday, September 25th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.40.
Check Out Our Latest Analysis on Hemab Therapeutics
Hemab Therapeutics Trading Up 2.4%
The business’s fifty day moving average is $42.69. The stock has a market capitalization of $1.48 billion and a PE ratio of -1.28.
Hemab Therapeutics (NASDAQ:COAG – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share for the quarter, missing the consensus estimate of ($0.63) by ($0.17). Equities research analysts predict that Hemab Therapeutics Holdings, Inc. will post -3.09 earnings per share for the current year.
Institutional Investors Weigh In On Hemab Therapeutics
Several institutional investors and hedge funds have recently bought and sold shares of COAG. Squarepoint Ops LLC acquired a new position in shares of Hemab Therapeutics in the 2nd quarter valued at $230,000. The Manufacturers Life Insurance Company bought a new stake in Hemab Therapeutics in the second quarter valued at about $688,000. Opaleye Management Inc. bought a new stake in Hemab Therapeutics in the second quarter valued at about $1,750,000. State Street Corp acquired a new position in Hemab Therapeutics in the second quarter worth about $2,825,000. Finally, Braidwell LP acquired a new position in Hemab Therapeutics in the second quarter worth about $5,877,000.
About Hemab Therapeutics
Hemab Therapeutics (NASDAQ: COAG) is a clinical-stage biopharmaceutical company developing treatments for serious and potentially life-threatening bleeding disorders. The company focuses on rare conditions for which existing therapies may be limited, inconvenient, or ineffective for some patients.
Hemab’s lead investigational program, HMB-001, is an engineered bispecific antibody designed to improve blood clotting by enhancing thrombin generation through inhibition of tissue factor pathway inhibitor.